✦ LIBER ✦

7109 Phase 2 results of ABT-869 treatment in patients with advanced renal cell cancer (RCC) after sunitinib failure

✍ Scribed by Tannir, N.; Wong, Y.; Kollmannsberger, C.; Ernstoff, M.S.; Perry, D.J.; Appleman, L.J.; Posadas, E.; Qian, J.; Ricker, J.L.; Michaelson, D.M.

Book ID: 123111566
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 49 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71442-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 trial of linifanib (ABT-869) in

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure

✍ Nizar M. Tannir; Yu-Ning Wong; Christian K. Kollmannsberger; Marc S. Ernstoff; D 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 322 KB

9013 Phase II results of ABT-869 treatme

9013 Phase II results of ABT-869 treatment in patients with non small cell lung cancer (NSCLC)

✍ Tan, E.; Goss, G.; Salgia, R.R.; Besse, B.; Gandara, D.R.; Hanna, N.; Ricker, J. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

7119 Genitourinary malignancies – Renal

7119 Genitourinary malignancies – Renal cancer Quality of life (QOL) in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) treated with pazopanib: results from a phase III double-blind, placebo-controlled trial

✍ Hawkins, R.; Hodge, R.; Chen, M.; Neary, M.; Pickard, A.S.; Sternberg, C. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 69 KB

7140 POSTER A Randomized Phase 2 Study o

7140 POSTER A Randomized Phase 2 Study of Axitinib Dose Titration in Patients With Advanced Renal Cell Carcinoma (RCC): Preliminary Pharmacokinetic and Ambulatory Blood Pressure (BP) Monitoring Results

✍ Grunwald, V.; Fishman, M.N.; Hutson, T.E.; Bair, A.; Chen, Y.; Kim, S.; Rini, B. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB

796 ORAL Bevacizumab, erlotinib, and ima

796 ORAL Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): Update of a Minnie Pearl Cancer Research Network phase I/II trial

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 135 KB

Interferon-α-2a with or without 13-cis r

Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma : Results of a randomized Phase II study (European Organization for Research and Treatment of Cancer Study 30951)

✍ Sophie D. Fosså; Gerald H. J. Mickisch; Pieter H. M. De Mulder; Simon Horenblas; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin